Capricor Therapeutics (0HTB) Financial Statements
Capricor Therapeutics Financial Overview
Capricor Therapeutics's market cap is currently $332.13M. The company's EPS TTM is $-2.45; its P/E ratio is -2.60; Capricor Therapeutics is estimated to report earnings on November 17, 2026, and the estimated EPS forecast is $-0.11. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 22.27M | $ 25.18M | $ 2.55M | $ 244.90K |
| Gross Profit | $ 0.00 | $ -27.70M | $ -11.27M | $ -19.27M | $ 244.90K |
| Operating Income | $ -108.14M | $ -42.56M | $ -24.08M | $ -29.70M | $ -20.94M |
| EBITDA | $ -100.11M | $ -39.04M | $ -21.22M | $ -28.49M | $ -19.78M |
| Net Income | $ -105.04M | $ -40.47M | $ -22.29M | $ -29.02M | $ -20.02M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 318.13M | $ 151.52M | $ 39.49M | $ 41.42M | $ 34.89M |
| Total Assets | $ 355.95M | $ 170.48M | $ 58.73M | $ 50.09M | $ 41.33M |
| Total Debt | $ 17.94M | $ 4.83M | $ 5.61M | $ 5.94M | $ 6.25M |
| Net Debt | $ -269.90M | $ -6.46M | $ -9.08M | $ -3.67M | $ -28.64M |
| Total Liabilities | $ 50.16M | $ 25.02M | $ 36.13M | $ 38.31M | $ 9.96M |
| Stockholders' Equity | $ 305.79M | $ 145.46M | $ 22.60M | $ 11.79M | $ 31.37M |
| Cash Flow | |||||
| Free Cash Flow | $ -72.72M | $ -41.53M | $ -27.64M | $ 1.56M | $ -18.01M |
| Operating Cash Flow | $ -69.81M | $ -40.00M | $ -25.60M | $ 4.92M | $ -16.81M |
| Investing Cash Flow | $ 97.48M | $ -116.18M | $ 5.11M | $ -35.07M | $ -1.20M |
| Financing Cash Flow | $ 248.89M | $ 152.77M | $ 25.58M | $ 4.87M | $ 20.23M |
Currency in USD
